Document Detail


Comparisons of exercise dose and symptom severity between exercisers and nonexercisers in women during and after cancer treatment.
MedLine Citation:
PMID:  22436836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Although numerous studies of the efficacy of exercise are reported, few studies have evaluated changes in characteristics of exercise dose in women with cancer both during and after cancer treatment.
OBJECTIVES: To describe the characteristics of exercise dose (i.e., frequency, duration, and intensity) and evaluate for differences in symptom severity (i.e., fatigue, sleep disturbance, depression, and pain) between women who did and did not exercise during and after cancer treatment.
METHODS: In a sample of 119 women, two groups were classified: exercisers and nonexercisers. Exercisers were defined as women who met specific criteria for frequency (three times per week), duration (20 minutes/session), intensity (moderate), and mode (aerobic). Nonexercisers were defined as women who did not meet all these criteria. Evaluation of exercise dose was completed at baseline (T1: the week before chemotherapy cycle 2), at the end of cancer treatment (T2), and at the end of the study (T3: approximately one year after the T1 assessment) using self-report exercise questionnaires.
RESULTS: Approximately 50% of the participants exercised during treatment and 70% exercised after treatment. At T1, exercisers had lower total fatigue, lower behavioral and sensory subscale fatigue scores, and lower depression scores (P = 0.038) than nonexercisers. No significant differences in sleep disturbance or pain were found between groups. At T2, exercisers had lower cognitive/mood subscale fatigue and depression scores than nonexercisers (P = 0.047). At T3, no significant differences were found between groups in any symptom severity scores.
CONCLUSION: Both during and after cancer treatment, achieving or maintaining exercise guideline levels were met by most patients. Further study is needed to examine the link between exercise dose and symptom severity.
Authors:
Maria H Cho; Marylin J Dodd; Bruce A Cooper; Christine Miaskowski
Related Documents :
22104346 - Knee extension exercises do not immediately change maximal voluntary quadriceps torque ...
3931936 - Exposure of hay fever subjects to an indoor environmental grass pollen challenge system.
1485166 - Possible mechanisms of formaldehyde-induced discomfort in the upper airways.
16406926 - A neuroanatomical comparison of humans and spotted hyena, a natural animal model for co...
15942766 - Influence of exercise duration on post-exercise steroid hormone responses in trained ma...
8083456 - Airway responsiveness to allergen is increased 24 hours after exercise challenge.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural     Date:  2012-03-19
Journal Detail:
Title:  Journal of pain and symptom management     Volume:  43     ISSN:  1873-6513     ISO Abbreviation:  J Pain Symptom Manage     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-07     Completed Date:  2012-09-17     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  8605836     Medline TA:  J Pain Symptom Manage     Country:  United States    
Other Details:
Languages:  eng     Pagination:  842-54     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
Affiliation:
School of Nursing, Samuel Merritt University, Oakland, California 94609, USA. mcho@samuelmerritt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / drug therapy,  rehabilitation*
Colorectal Neoplasms / drug therapy,  rehabilitation*
Exercise / physiology*
Exercise Therapy*
Fatigue
Female
Humans
Middle Aged
Ovarian Neoplasms / drug therapy,  rehabilitation*
Questionnaires
Severity of Illness Index
Women
Grant Support
ID/Acronym/Agency:
CA83316/CA/NCI NIH HHS; MO1 RR00079/RR/NCRR NIH HHS; R01 CA083316-01/CA/NCI NIH HHS; R01 CA083316-02/CA/NCI NIH HHS; R01 CA083316-03/CA/NCI NIH HHS; R01 CA083316-04/CA/NCI NIH HHS; R01 CA083316-05/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients...
Next Document:  Integrated model for assessing the cost and CO(2) emission (IMACC) for sustainable structural design...